Tokyo Guidelines 2018 diagnostic criteria and severity grading of acute cholecystitis (with videos)

Citation for published version:

Digital Object Identifier (DOI):
10.1002/jhbp.515

Link:
Link to publication record in Edinburgh Research Explorer

Published in:
Journal of Hepato-Biliary-Pancreatic Sciences

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Guideline

Tokyo Guidelines 2018 diagnostic criteria and severity grading of acute cholecystitis (with videos)


The author’s affiliations are listed in the Appendix.

Corresponding author:
Tadahiro Takada, M.D., Ph.D.
Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan
Email: t-takada@jshbps.jp

Key word: Cholecystitis, acute / Diagnosis/ Diagnostic Imaging/ Severity of Illness Index / Guidelines

Abstract

TG13 Tokyo guidelines for acute cholangitis and cholecystitis were globally disseminated and various clinical researches about the management of acute cholecystitis were reported by lots of researchers and clinicians from all over the world. The 1st edition of Tokyo Guidelines 2007 (TG07) was revised in 2013. According to that revision, the TG13 diagnostic criteria of acute cholecystitis provided better specificity and higher diagnostic accuracy. Thorough our literature search about diagnostic criteria for acute cholecystitis, new and strong evidence that had been released from 2013 to 2017 was not found with

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jhbp.515
This article is protected by copyright. All rights reserved.
serious and important issues about using TG13 diagnostic criteria of acute cholecystitis. On the other hand, the TG13 severity grading for acute cholecystitis have been validated in numerous studies. As a result of review, the TG13 severity grading for acute cholecystitis was significantly associated with parameters including 30-day overall mortality, length of hospital stay, conversion rates to open surgery, and medical costs. In terms of severity assessment, breakthrough and intensive literature for revising severity grading was not reported. Consequently, TG13 diagnostic criteria and severity grading were judged from numerous validation studies as useful indicators in clinical practice and adopted as TG18/TG13 diagnostic criteria and severity grading of acute cholecystitis without any modification.

Introduction

The TG13 diagnostic criteria and severity grading of acute cholecystitis [1] have become widely adopted in recent years, being used not only in clinical practice but also in numerous research studies on this disease. These diagnostic criteria and severity grading of acute cholecystitis constitute guidelines produced on the basis of the consensus achieved during discussions by global experts at the Tokyo Consensus Meeting held in 2007, and the first version was published as Tokyo Guidelines 2007(TG07) [2]. Based on studies that have found the lifespan of guidelines to be around five years [3], the Tokyo Guidelines Revision Committee revised the TG07 guidelines in 2013. Validation of the TG07 diagnostic criteria and severity grading of acute cholecystitis had identified two issues with the diagnostic criteria in particular: the use of two categories for deciding a definitive diagnosis led to ambiguity in clinical practice, and criteria for suspected diagnosis were not specified [4]. That validation study found that the sensitivity and specificity of a definitive diagnosis according to TG07 were 84.9% and 50.0%, respectively, whereas Murphy's sign was of 20.5% sensitivity and 87.5% specificity. The diagnostic accuracy of the TG07 diagnostic criteria was thus significantly greater than that of Murphy's sign ($p = 1.31 \times 10^{-10}$). However, the authors pointed out that further improvement was required in the specificity of the diagnostic criteria for definitive diagnosis. Rather than changing the factors used for assessment, further consideration of new diagnostic criteria led to the decision to change the criteria by designating the presence of local signs of...
inflammation and systemic signs of inflammation as indicating a suspected diagnosis, and requiring
confirmation by imaging findings in addition to these two factors for a definitive diagnosis. These new
diagnostic criteria were validated by a multicenter joint study of 451 patients with acute cholecystitis [5],
which found that their use improved sensitivity and specificity to 91.2% and 96.9%, respectively. On the
basis of this result, the diagnostic criteria of TG13 were revised to reflect this new designation. At that
point, no major problems with the use of the TG07 severity assessment criteria in clinical practice had
been reported and no new evidence was available; therefore, the severity assessment criteria were adopted
unchanged in TG13. However, Takada et al. expressed concern with the lack of evidence at the time
preparations for the publication of TG13 were completed [6]. A large-scale epidemiological survey of
acute biliary infection was therefore launched as a Japan-Taiwan Collaborative project: Defining the best
practice of managing Acute Cholangitis and Cholecystitis since September 2012. This study gathered "big
data" from over 7000 cases. Data from over 5000 patients with acute cholecystitis in that study were then
used to describe patient characteristics, treatment status, and the status of use of the TG13 diagnostic
criteria and severity grading in clinical practice, and this was published as a descriptive study [7]. A
large-scale validation of the TG13 severity grading of acute cholecystitis was then carried out on the basis
of those results [8], providing evidence for the current revisions. The inclusion of validation by "big data"
in revision work on guidelines is far from common, but the work of revising TG18 can justly be said to be
proceeding on the basis of clinical data.

In the Tokyo Guidelines Revision Committee, we searched for evidence published since TG13, and
identified 216 articles related to the diagnostic criteria and severity grading of acute cholecystitis,
including 19 randomized controlled trials (RCTs). Work on revision began in 2016. Based on these articles,
we found that when considering new evidence gathered on the TG13 diagnostic criteria and severity
grading of acute cholecystitis, such as validation studies, there was relatively little evidence concerning
diagnostic criteria, with most validation studies instead being concerned with severity grading [9-13].
Some studies found that severity grading plays a useful role in predicting vital prognosis [9], and others
that the length of hospitalization and the laparotomy conversion rate were significantly higher in more

This article is protected by copyright. All rights reserved.
severe cases [10]. Other studies, however, found that severe cholecystitis may be amenable to surgical treatment, even if percutaneous cholecystostomy is not always feasible and open cholecystectomy may be required [11,12]. Endo et al. carried out multivariate analysis of "big data" and used the results to propose a new treatment strategy for Grade III in accordance with TG13 severity grading [14]. Although the prognosis for acute cholecystitis is far from poor, survival prognosis is still determined by severity grading, and the discussion during the 2007 Tokyo consensus meeting in which it was decided that acute cholecystitis patients with organ failure affecting survival should therefore be graded as Grade III (severe) is still a recent memory.

In these present revisions, in light of the evidence accumulated so far, we report on our investigation of whether the diagnostic criteria and severity grading should be changed for TG18, and if so how. We also provide new information on diagnostic imaging in relation to diagnosis and severity grading.

CQ1. Is TG13 diagnostic criteria of acute cholecystitis recommended to use as TG18 diagnostic criteria?  

[Foreground Question(Clinical question)]

The TG13 diagnostic criteria for acute cholecystitis have high sensitivity and specificity and good diagnostic yield; therefore, their use as the TG18 diagnostic criteria for acute cholecystitis is recommended.

(Recommendation 1, Level C)

To date, no diagnostic criteria for acute cholecystitis meriting that title have been established other than TG13 [1]. However, studies of the diagnostic yield of the TG13 diagnostic criteria are limited [5, 15, 16]. Studies have found that diagnostic accuracy ranges from 94.0% [5] to 60.4% [15] if pathological samples are used as the gold standard. In the former study, the sensitivity and specificity of the diagnostic criteria for acute cholecystitis were 91.2% and 96.9%, compared with 83.1% and 37.5% in the latter study.

This article is protected by copyright. All rights reserved.
However, the latter study found that neutrophil count was the only independent predictor of acute cholecystitis for which a significant difference was evident on the basis of multivariate analysis [15]. The use of neutrophil count alone for the definitive diagnosis of acute cholecystitis is unrealistic. The WSES guidelines for acute calculous cholecystitis, which are restricted to cholecystitis due to calculi, recommend the combined use of clinical, laboratory, and imaging findings for diagnosis, without designating new diagnostic criteria [16]. The TG13 diagnostic criteria for acute cholecystitis constitute exactly this combination, and we considered that they share the same concept for the designation of diagnostic criteria.

A Japanese study of the association between diagnostic criteria and factors such as length of hospitalization and medical costs found statistically significant differences between definitive and suspected diagnoses [17], demonstrating the effectiveness of these diagnostic criteria. In light of the results of such validation studies, we considered that there are no major problems with the TG13 diagnostic criteria for acute cholecystitis, and recommend that they be used unchanged as the TG18/TG13 diagnostic criteria (Table 1).

CQ2. Is procalcitonin measurement useful for diagnosing and severity grading of acute cholecystitis?

[Future research question]

Few studies have addressed procalcitonin (PCT) in acute cholecystitis, and at present its value cannot be assessed.

(Level C)

Although systematic reviews of the value of procalcitonin (PCT) for the diagnosis and severity grading of sepsis have been published [18, 19], a meta-analysis has found that inconsistencies in study design mean that it is not helpful in distinguishing between sepsis and non-sepsis [20]. There has been only a single clinical study limited to patients with acute cholecystitis: this study found that it was correlated with the TG13 severity grading classification [21].
A number of studies that have collected cases of patients with acute cholangitis have reported that PCT is correlated with severity [22, 23, 24]. At this point, there is insufficient evidence to investigate the value of PCT measurement in acute cholecystitis, and as more evidence must be gathered in order for this to be assessed, this issue is therefore designated as a question for future research.

CQ3. Is ultrasonography recommended for diagnosing acute cholecystitis?

[Foreground Question (Clinical question)]

Although the diagnostic criteria for the diagnosis of acute cholecystitis by ultrasonography and its diagnostic yield vary in different studies, its low invasiveness, widespread availability, ease of use, and cost-effectiveness make it recommended as the first-choice imaging method for the morphological diagnosis of acute cholecystitis.

(Recommendation 1, Level C)

The use of ultrasonography (US) in acute cholecystitis has been well reported, and its ease of use and non-invasive modality have been described in case series studies [15, 25–28]. However, the diagnostic yield described in those articles varies according to the device, assessment criteria, and diagnostic criteria used in each of the studies, all of which were of small numbers of patients in single institutions. All studies that have compared the diagnostic yield of hepatobiliary scintigraphy (HIDA scanning) with that of US have found that the diagnostic yield is higher for HIDA scanning [26,27], but diagnostic imaging with US is nevertheless recommended in three newly proposed guidelines despite its limited diagnostic yield [16, 29,30].

US is comparatively inexpensive compared with modalities such as computed tomography (CT) and magnetic resonance imaging (MRI), and its non-invasive nature and comparatively high diagnostic yield make it the best option for the diagnostic imaging of acute cholecystitis [31,32]: its rate of use in clinical practice is reported to be 61.3% [7].
A meta-analysis comparing methods of diagnostic imaging for acute cholecystitis reported that US has 81% sensitivity (95% CI: 0.75–0.87) and 83% specificity (95% CI: 0.74–0.89) [33] (Fig. 1).

According to the TG13 diagnostic criteria for acute cholecystitis, diagnostic imaging findings are required for a definitive diagnosis, and US is the recommended method of diagnostic imaging (Fig. 2) (Supplement Movie 1).

CQ4. Is color or power Doppler sonography useful for diagnosing acute cholecystitis?

[Future Research Question]

| No recent studies have found that color or power Doppler sonography is useful for diagnosing acute cholecystitis. In terms of the underlying principles, the evaluation of blood flow by Doppler sonography is strongly affected by factors such as device performance and the patient's body type, which makes quantification difficult, and the designation of standard levels for use in diagnosis is therefore inappropriate. (Level: D) |

A study of the use of color Doppler sonography in acute cholecystitis found that although it was useful for the diagnosis of gallbladder adhesions, it was not predictive of the degree of surgical difficulty [34]. In our search of the color Doppler sonography literature, we were unable to identify any articles concerning the diagnosis of acute cholecystitis. None of the literature stated the type of device or device settings used (Doppler gain, high-pass filter, Doppler frequency, or speed range) or described patient characteristics (such as body wall thickness), and evaluation was subjective and qualitative in all cases. Potential problems include performance bias, detection bias, and inaccuracy. Although US in itself is not invasive and it is used more widely than other methods of morphological diagnosis, the use of color Doppler sonography for assessment is risky. Insufficient evidence is available to consider its value; as it cannot be assessed until further evidence has been gathered, this is regarded as a question for future research (Fig. 3).
CQ5. Is MRI/MRCP useful for diagnosing acute cholecystitis?

[Foreground Question(Clinical question)]

<table>
<thead>
<tr>
<th>MRI/MRCP is useful for diagnosing acute cholecystitis.</th>
</tr>
</thead>
<tbody>
<tr>
<td>It is recommended if abdominal ultrasonography does not provide a definitive diagnosis.</td>
</tr>
</tbody>
</table>
(Recommendation 2, Level B)

Abdominal US should be the first method of diagnostic imaging used for acute cholecystitis. However, as a causative stone in the gallbladder or bile duct may not always be clearly identifiable on abdominal US and the diagnosis of gangrenous cholecystitis may be difficult (see CQ7), it is also recommended that contrast-enhanced CT or MRI be performed if required[36,37].

The generally accepted imaging findings of acute cholecystitis are thickening of the gallbladder wall (≥4 mm), enlargement of the gallbladder (long axis ≥8 cm, short axis ≥4 cm), gallstones or retained debris, fluid accumulation around the gallbladder, and linear shadows in the fatty tissue around the gallbladder [38].

A 2012 meta-analysis of the MRI diagnosis of acute cholecystitis indicated the value of MRI/MRCP as shown in Figure 1, with the diagnostic yield of MRI for acute cholecystitis providing 85% sensitivity (95% CI: 0.66–0.95) and 81% specificity (95% CI: 0.69–0.90)[33]. However, that meta-analysis was based on three cohort studies and a cross-sectional study performed around the turn of the millennium, and the fact that contrast-enhanced MRI and MRCP were not yet in use at that point must be taken into account. Even non-contrast MRI/MRCP provides good visualization of thickening of the gallbladder wall, fluid retention around the gallbladder wall, and enlargement of the gallbladder, and one study has found that it is not inferior to contrast-enhanced MRI [39]. The anatomy of the biliary system is easy to assess on MRCP (by the visualization of accessory hepatic ducts and the common bile duct), making it useful for preoperative investigation. In terms of differentiation from chronic cholecystitis, thickening of the gallbladder wall and dense staining of the gallbladder bed in the early phase of contrast-enhanced MRI have been found to have 92% specificity for the diagnosis of acute cholecystitis [40] (Fig. 4), and another study also found that abnormal signals in fatty tissue around the gallbladder on MRI T2-weighted imaging had higher specificity.
compared with CT findings [41] (Fig. 5). MRCP enables the anatomy of the biliary tract to be visualized without the use of a contrast agent, and is thus extremely useful. Although MRI/MRCP is expensive [16] compared with abdominal US, which is generally the lowest-cost method of imaging, its diagnostic yield is somewhat better than that of abdominal US, and its use is therefore recommended when abdominal US does not provide a definitive diagnosis. It is noteworthy that the image quality of MRI/MRCP may be deteriorated due to a patient with acute abdominal pain who may not be able to hold his/her breath or keep his/her at rest.

**CQ6: Is TG13 severity grading of acute cholecystitis recommended to use as TG18 severity grading?**

[Foreground Question (Clinical question)]

Grade III (severe) acute cholecystitis in the TG13 severity grading of acute cholecystitis causes systemic symptoms due to organ damage and affects survival prognosis. The TG13 severity grading of acute cholecystitis is recommended for use as the TG18 severity grading of acute cholecystitis as a useful indicator from the perspective of predicting prognosis, among others.

(Recommendation 1, Level C)

(Addendum: Although moderate acute cholecystitis does not result in organ damage, this is still a risk, and as serious local complications may also arise, assessment using this severity grading may also be used to predict this risk.)

Grade III (severe) acute cholecystitis in the TG13 severity grading of acute cholecystitis is described as acute cholecystitis associated with organ system dysfunction, which in some circumstances may require treatment in an intensive care unit [1]. Severe acute cholecystitis is thus a condition that affects vital prognosis. However, the mortality rate for acute cholecystitis is only around 1% [7,42], and some studies, including case series studies, have also failed to find any association between severity grade and prognosis [12, 43]. Nevertheless, logistic regression analysis of the prediction of prognosis for acute cholecystitis...
This article is protected by copyright. All rights reserved.
of gallbladder, wall edema, and preoperative adverse events [49]. The authors found that when two or more factors were positive this system had 54.9% sensitivity (95% CI: 44.1%–65.2%) and 81.2% specificity (95% CI: 75.4%–85.9%), and when three or more factors were positive it had 15.9% sensitivity (95% CI: 9.5%–25.3%) and 98.6% specificity (95% CI: 95.9%–99.5%). Neither of the two newly proposed guidelines indicate criteria for severity grading [16,29]. Studies have found that surgery for patients classed as Grade III according to the TG13 severity grading is feasible even if percutaneous cholecystectomy is not always performed, with conversion or subtotal cholecystectomy also possible procedures [11,12]. The TG13 severity grading cannot be used to assess surgical difficulty. If a set of severity grading criteria including such an element of surgical difficulty were to be produced in future, a large-scale validation study taking account of a large number of factors would be required. Rather than changing the Grade III assessment criteria, it may be possible to subdivide Grade III cases to enable safe surgery and select the appropriate treatment strategy. On this point, Endo et al. used multivariate analysis to investigate predictive factors in Grade III cases, and showed that factors including jaundice, neurological dysfunction, and respiratory dysfunction were associated with vital prognosis [14] (Table 6).

The assessment criteria used in the TG13 severity grading for acute cholecystitis have been validated in numerous studies, are significantly associated with parameters including vital prognosis, length of hospital stay, conversion to open surgery, and medical costs, and are useful indicators in clinical practice. Their use as the TG18/TG13 severity assessment criteria is therefore recommended (Table 7).
CQ7. What method of diagnostic imaging is recommended for diagnosing gangrenous cholecystitis?

[Foreground Question (Clinical question)]

Contrast-enhanced CT or contrast-enhanced MRI is recommended for diagnosing gangrenous cholecystitis.

(Recommendation 2, Level C)

Gangrenous cholecystitis exhibits specific findings on dynamic CT, including irregular thickening of the gallbladder wall, poor contrast enhancement of the gallbladder wall (interrupted rim sign), increased density of fatty tissue around the gallbladder, gas in the gallbladder lumen or wall, membranous structures within the lumen (intraluminal flap or intraluminal membrane), and peri-gallbladder abscess [50] (Fig. 6). These signs of irregularity or rupture of the gallbladder wall are often underestimated on abdominal US [35], and studies have found that the presence of the interrupted rim sign on contrast-enhanced CT has 73% sensitivity and 95% negative predictive value [38] and that the appearance of intraluminal membranous structures on contrast-enhanced MRI has 80% diagnostic accuracy [51], exceeding the diagnostic yield of abdominal US. A retrospective image analysis study of patients diagnosed with acute cholecystitis also found that a combination of the perfusion defect of the gallbladder wall and no identifiable calculi had 92% diagnostic accuracy, 88.2% sensitivity, and 100% specificity for the diagnosis of acute gangrenous cholecystitis [51].

Gangrenous cholecystitis is classed as moderate (Grade II) acute cholecystitis according to the TG13 severity grading, and is a serious condition that may cause organ damage if its diagnosis is delayed.

Abdominal US is generally the lowest-cost method of imaging, and contrast-enhanced CT and contrast-enhanced MRI are expensive tests [52]. However, the diagnostic yield of contrast-enhanced CT and contrast-enhanced MRI is better than that of abdominal US for gangrenous cholecystitis, and the use of one of these methods is particularly recommended for patients with suspected gangrenous cholecystitis (Supplement Movie 2,3).
CQ8. What method of diagnostic imaging is recommended for diagnosing emphysematous cholecystitis?

[Foreground Question (Clinical question)]

CT is recommended for diagnosing emphysematous cholecystitis.

(Recommendation 2, Level D)

Emphysematous cholecystitis is an inflammation caused by aerogenic bacteria, and has a high perforation rate. It causes potentially fatal complications including intra-abdominal abscess, generalized peritonitis, gas gangrene of the abdominal wall, and sepsis; its clinical course is often extremely rapid. In TG13 it is classed as moderate acute cholecystitis (severe local inflammatory findings) [1]. An accurate assessment of the presence of gas within the gallbladder wall is important for the diagnosis of emphysematous cholecystitis, but in abdominal US it is very often difficult to distinguish between intramural gas, which appears hyperechoic, and porcelain gallbladder. As gas is sometimes found to be present within the gallbladder lumen after biliary surgery or sphincterotomy, distinguishing between intraluminal and intramural gas is important, but this may be difficult to diagnose correctly on abdominal US. Gas appears clearly hypodense on CT (usually near the –1000 HU), making detection extremely easy[36,50]. Intramural gas is often present also in gangrenous cholecystitis[38,51]. Contrast-enhanced CT should be considered for the evaluation of complications such as intraperitoneal abscess and peritonitis. Gas appears as a signal void on MRI[53], however this modality is inferior to CT in terms of spatial resolution for the detection of minute amounts of gas. Plain CT is thus the most useful method for diagnosing emphysematous cholecystitis (Fig.7).
The Results of discussion about the diagnostic criteria and severity grading for acute cholecystitis at the public hearing

In A-PHPBA at Yokohama Congress Center on June 9, 2017, public hearing was held and gathered various opinions about this topic. It was decided that TG13 diagnostic criteria and severity grading would be adopted TG18 without any modification by final vote (Fig. 8).

Acknowledgements
We express our deep gratitude to the Japanese Society of Hepato-Biliary-Pancreatic Surgery, the Japanese Society of Abdominal Emergency Medicine, the Japanese Society of Surgical Infection, and the Japan Biliary Association, for their substantial support and guidance in the preparation of this article. We also would like to express our deep gratitude to the Japanese Society of Hepato-Biliary-Pancreatic Surgery for the Article Processing Managing Office of the Tokyo Guidelines 18 for preparing this publication. We appreciate all secretariats of the Japanese Society of Hepato-Biliary-Pancreatic Surgery for their technical support.

Conflicts of interest
Anthony Yuen Bun TEOH has received consultant fees from Boston Scientific Corporation, USA, Cook Medical, USA, and Taewoong Medical, Korea. Goro Honda has received honoraria from Johnson and Johnson and Medtronic.

Appendix:
Masamichi Yokoe and Yoshinori Noguchi, Department of General Internal Medicine, Japanese Red Cross Nagoya Daini Hospital, Aichi, Japan; Jiro Hata, Department of Endoscopy and Ultrasound, Kawasaki Medical School, Okayama, Japan; Tadahiro Takada and Fumihiko Miura, Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan; Steven M. Strasberg, Section of Hepato-Pancreato-Biliary Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO, USA; Horacio J. Asbun, Department of Surgery, Mayo Clinic College of Medicine, Jacksonville, FL, USA; Go Wakabayashi, Department of Surgery, Ageo Central General Hospital, Saitama, Japan; Kazuto Kosaka, Department of Radiology, Kanazawa University Graduate School of Medical Sciences, Itaru Endo, Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Kanagawa, Japan; Daniel J. Deziel, Department of Surgery, Rush University Medical Center, Chicago, IL, USA; Kohji Okamoto, Department of Surgery, Center for Gastroenterology and Liver Disease, Kitakyushu City Yahata

This article is protected by copyright. All rights reserved.
Accepted Article

Hospital, Fukuoka, Japan; Tsann-Long Hwang and Miin-Fu Chen, Division of General Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; Wayne Shih-Wei Huang, Department of Surgery, Show Chwan Memorial Hospital, Changhua, Taiwan; Chen-Guo Ker, Department of Surgery, Yuan’s General Hospital, Kaohsiung, Taiwan; Eduard Jonas, Surgical Gastroenterology/Hepatopancreatobiliary Unit University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa; Ho-Seong Han and Yoo-Seok Yoon, Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Korea; In-Seok Choi, Department of Surgery, Konyang University Hospital, Daejeon, Korea; Dong-Sup Yoon, Department of Surgery, Yonsei University Gangnam Severance Hospital, Seoul, Korea; Satoru Shikata, Director, Mie Prefectural Ichishi Hospital, Mie, Japan; Tomohiko Ukai, Department of Family Medicine, Mie Prefectural Ichishi Hospital, Mie, Japan; Ryota Higuchi and Masakazu Yamamoto, Department of Surgery, Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo, Japan; Toshifumi Gabata, Director, General Kanazawa University Hospital, Yasuhisa Mori, Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Yukio Iwashita, Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Oita, Japan; Taizo Hibi, Department of Surgery, Keio University School of Medicine, Tokyo, Japan; Palepu Jagannath, Department of Surgical Oncology, Lilavati Hospital and Research Centre, Mumbai, India; Eduard Jonas, Surgical Gastroenterology/Hepatopancreatobiliary Unit University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa; Kui-Hin Liau, Liau KH Consulting PL, Mt Elizabeth Novena Hospital, Singapore, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Christos Dervenis, First Department of Surgery, Agia Olga Hospital, Athens, Greece; Dirk Joan Gouma, Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands; Daniel Cherqui, Hepatobiliary Center, Paul Brousse Hospital, Villejuif, France; Giulio Belli, Department of General and HPB Surgery, Loreto Nuovo Hospital, Naples Italy; O. James Garden, Clinical Surgery, University of Edinburgh, Edinburgh, UK; Mariano Eduardo Giménez, Chair of General Surgery and Minimal Invasive Surgery “Taquini”, University of Buenos Aires, DAICIM Foundation, Buenos Aires, Argentina; Eduardo de Santibañes, Department of Surgery, Hospital Italiano,

This article is protected by copyright. All rights reserved.
References


This article is protected by copyright. All rights reserved.


This article is protected by copyright. All rights reserved.


**Figure legend**

**Fig. 1** Forest plot. Paired forest plot of summary estimates for sensitivity and specificity. The overall summary estimates of sensitivity and specificity for cholescintigraphy, US, and MR imaging are plotted in pairs. Error bars = calculated 95% CIs. (Source: Reference 33)

**Fig. 2** Typical ultrasound images of acute cholecystitis.

- a: Pericholecystic fluid. Pericholecystic fluid is demonstrated to the left side of the gallbladder. Gallstones and debris are also seen in the gallbladder.
- b: An intraluminal flap seen in a gangrenous cholecystitis. A linear echogenic line representing the intraluminal flap is demonstrated.

**Fig. 3** Typical ultrasound images of acute cholecystitis

- a: Color Doppler images of acute cholecystitis. Increased intraluminal blood flow is demonstrated. However it is not always easy to estimate the intraluminal flow since the sensitivity of color Doppler imaging is influenced by several factors such as the settings of the filter, velocity range, frequency of the ultrasound beam, the patients’ constitutions, and the limitations of the equipment.
- b: Superb Microvascular Imaging of acute cholecystitis. Superb Microvascular imaging, which is more sensitive than the conventional color Doppler in the detection of blood flow, shows the increased intraluminal flow of the gallbladder in a patient with acute cholecystitis. Still, the same problem as described in the figure legend of Fig. 3a remains so it is difficult to make use of these Doppler imagings as an objective method for the diagnosis of acute cholecystitis.

**Fig. 4** Typical MR images of acute cholecystitis comparing contrast-enhanced CT. Man in 40s with acute cholecystitis due to gallstones. Dynamic contrast enhanced MRI and CT are shown. Early phase (a) and portal venous phase (b) of contrast-enhanced MRI
Early phase (c) and portal venous phase (d) of contrast-enhanced CT. Numerous signal voids are visible in the gallbladder (a, arrowhead which indicates the gallstones). Clear contrast enhancement of the gallbladder wall is evident (b, arrows). This contrast enhancement of the wall is more clearly visualized on MRI compared with contrast-enhanced CT, and gallstone visualization is also better on MRI than on CT. To identify gallstone, T2 weighted MRI is also helpful (image is not shown).

**Fig. 5** Typical MR images and MRCP of acute cholecystitis. Man in 70s with acute cholecystitis due to gallstones. MR T2 weighted image (ssfse: single shot fast spin echo) (a), diffusion weighted image (b), and MRCP (c). On T2 weighted image of MRI (a), a hypointense gallstone (a, arrowhead) is visible in the gallbladder. The gallbladder is enlarged, with thickening of the wall (a, arrow). On diffusion weighted image of MRI (b), thickening of the gallbladder wall (b, arrows) is clearly evident. The deposition of debris is visualized as a hyperintensity (b, *) at the neck of the gallbladder. On 2D MRCP image (40mm slice thickness) (c), the aberrant posterior hepatic duct (c, arrow) is clearly visualize. The asterisk indicates the neck of the gallbladder.

**Fig. 6** Typical CT images of gangrenous cholecystitis. Woman in her 70s with gangrenous cholecystitis (acute acalculous cholecystitis). Dynamic contrast enhanced CT (a, plain; b, early phase; c, equilibrium phase). Enlargement of the gallbladder, thickening of the gallbladder wall, and edematous lesions beneath the gallbladder serosa are evident on plain CT (arrows). On contrast enhanced CT (b, c), irregularity of the gallbladder wall and the partial lack of contrast enhancement can be seen (arrows) as the characteristic appearance of gangrenous cholecystitis. Transient early-phase staining of the hepatic parenchyma (b) and edematous changes to the hepatoduodenal ligament (c, arrowhead) are also apparent, suggesting the spread of inflammation.
**Fig. 7** Typical CT, US, and MRI findings of gangrenous cholecystitis. Man in his 80s with emphysematous cholecystitis. Chest X-ray (a, inset picture is a magnification of the squared area), plain CT (b), dynamic contrast enhanced CT: early phase (c), equilibrium phase (d). On chest X-ray, abnormal gas is apparent in the right upper abdomen. Gas is present both within the gallbladder lumen (a, *) and the gallbladder wall (a, arrows). On plain CT, gas is evident both within the gallbladder wall and the gallbladder lumen. Contrast enhancement is apparent in the wall at the neck of the gallbladder (arrowhead). Inflammation has spread beneath the duodenal mucosa, and an abscess is also present (*).

**Fig. 8** Public hearing final voting outcome

*Supporting Information*

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site:

**Supplement Movie 1**: Acute cholecystitis.
Gallbladder swelling, wall thickening with pericholecystic fluid, massive debris and stone impaction are demonstrated.

**Supplement Movie 2**: Gangrenous cholecystitis.
Gallbladder swelling, wall thickening, hypoechoic layer and massive debris are demonstrated. However, it is difficult to diagnose acute gangrenous cholecystitis or not for this case by only these US findings.

**Supplement Movie 3**: Gangrenous cholecystitis.
Gallbladder enlargement, massive debris and stone impaction are demonstrated. However, it is difficult to diagnose acute gangrenous cholecystitis or not for this case by only these US findings.

This article is protected by copyright. All rights reserved.
Table 1 TG18/TG13 Diagnostic criteria for acute cholecystitis

A. Local signs of inflammation etc.:
(1) Murphy’s sign, (2) RUQ mass/pain/tenderness

B. Systemic signs of inflammation etc.:
(1) Fever, (2) elevated CRP, (3) elevated WBC count

C. Imaging findings:
Imaging findings characteristic of acute cholecystitis

Suspected diagnosis: One item in A + one item in B
Definite diagnosis: One item in A + one item in B + C

Cited from Ref.[5]

Notes: acute hepatitis, other acute abdominal diseases, and chronic cholecystitis should be excluded. RUQ right upper abdominal quadrant, CRP C-reactive protein, WBC white blood cell. The TG13 diagnostic criteria of acute cholecystitis was judged from numerous validation studies as useful indicators in clinical practice and adopted as TG18 diagnostic criteria without any modification.

Table 2 Relationship between severity and 30-days overall mortality*

<table>
<thead>
<tr>
<th>Severity grading</th>
<th>Grade I</th>
<th>Grade II</th>
<th>Grade III</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>n= 1339</td>
<td>n= 1702</td>
<td>n= 680</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30 days mortality</td>
<td>15 (1.1%)</td>
<td>13 (0.8%)</td>
<td>37 (5.4%)</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

*Data from Yokoe et al. [8]

Table 3 Length of hospital stay

<table>
<thead>
<tr>
<th>References</th>
<th>Year</th>
<th>n</th>
<th>Grade I</th>
<th>Grade II</th>
<th>Grade III</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cheng [44]</td>
<td>2014</td>
<td>103</td>
<td>7.3±3.5</td>
<td>9.2±3.9</td>
<td>15.2±8.5</td>
<td>p&lt;0.05</td>
</tr>
<tr>
<td>Kamalapurkar* [11]</td>
<td>2014</td>
<td>84</td>
<td>5(4-8)</td>
<td>12(8-16)</td>
<td>p&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Wright* [10]</td>
<td>2015</td>
<td>445</td>
<td>3(1-16)</td>
<td>4(1-33)</td>
<td>7(1-60)</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Ambe§ [13]</td>
<td>2015</td>
<td>138</td>
<td>6.0±2.7</td>
<td>7.8±3.3</td>
<td>10.4±6.1</td>
<td>p=0.02</td>
</tr>
<tr>
<td>Amirthalingam** [12]</td>
<td>2016</td>
<td>149</td>
<td>4.46(2-14)</td>
<td>6.24(1-41)</td>
<td>9.31(3-21)</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Hayasaki [17]</td>
<td>2016</td>
<td>171</td>
<td>4.3±2.5</td>
<td>11.0±11.6</td>
<td>20.8±13.5</td>
<td>p&lt;0.001</td>
</tr>
</tbody>
</table>

Data are presented as mean days±SD. *:median(range), **:median(interquartile range), §:postoperative length of hospital stay

This article is protected by copyright. All rights reserved.
### Table 4 Conversion rate from laparoscopic cholecystectomy to open surgery

<table>
<thead>
<tr>
<th>References</th>
<th>Year</th>
<th>n</th>
<th>Grade I</th>
<th>Grade II</th>
<th>Grade III</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asai [45]</td>
<td>2014</td>
<td>225</td>
<td>7/105</td>
<td>22/119</td>
<td>0/1</td>
<td>0.0279</td>
</tr>
<tr>
<td>Wright [10]</td>
<td>2015</td>
<td>445</td>
<td>7/92</td>
<td>31/121</td>
<td>9/26</td>
<td>0.001</td>
</tr>
<tr>
<td>Amirthalingam [12]</td>
<td>2016</td>
<td>149</td>
<td>2/84</td>
<td>6/49</td>
<td>0/16</td>
<td>0.03</td>
</tr>
</tbody>
</table>

### Table 5 Complications (Morbidities)

<table>
<thead>
<tr>
<th>References</th>
<th>Year</th>
<th>n</th>
<th>Grade I</th>
<th>Grade II</th>
<th>Grade III</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cheng [44]</td>
<td>2014</td>
<td>103</td>
<td>3/31</td>
<td>7/25</td>
<td>9/20</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Wright [10]</td>
<td>2015</td>
<td>445</td>
<td>4/137</td>
<td>6/191</td>
<td>13/117</td>
<td>0.003</td>
</tr>
<tr>
<td>Ambe [13]</td>
<td>2015</td>
<td>138</td>
<td>7/79</td>
<td>5/33</td>
<td>12/26</td>
<td>0.01</td>
</tr>
</tbody>
</table>

This article is protected by copyright. All rights reserved.
Table 6 Survival analysis of 30-day mortality in patients with Grade III AC**

<table>
<thead>
<tr>
<th>Charlson Comorbidity Index</th>
<th>Survivor (n=591)</th>
<th>Non-survivor (n=20)</th>
<th>Univariate p-value</th>
<th>Multivariate p-value</th>
<th>odds ratio</th>
<th>95%CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 0~5</td>
<td>304</td>
<td>7</td>
<td>0.148</td>
<td>0.380</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 6≤</td>
<td>287</td>
<td>13</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jaundice</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 -</td>
<td>477</td>
<td>9</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>6.470</td>
<td>(2.446 - 17.110)</td>
</tr>
<tr>
<td>1 +</td>
<td>114</td>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurological</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 -</td>
<td>518</td>
<td>12</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>4.346</td>
<td>(1.640 - 11.515)</td>
</tr>
<tr>
<td>1 +</td>
<td>73</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 -</td>
<td>528</td>
<td>13</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>5.843</td>
<td>(2.052 – 16.635)</td>
</tr>
<tr>
<td>1 +</td>
<td>63</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

** Data from Endo et al.14

Table 7 TG18/TG13 Severity assessment criteria for acute cholecystitis

**Grade III (Severe) acute cholecystitis**

“Grade III” acute cholecystitis is associated with dysfunction of any one of the following organs/systems
1. Cardiovascular dysfunction (hypotension requiring treatment with dopamine≧5μg/kg per min, or any dose of Norepinephrine)
2. Neurological dysfunction decreased level of consciousness
3. Respiratory dysfunction PaO2/FiO2 ratio<300
4. Renal dysfunction Oliguria, creatinine>2.0mg/dl
5. Hepatic dysfunction PT-INR>1.5
6. Hematological dysfunction Platelet count<100,000/mm³

**Grade II (Moderate) acute cholecystitis**

“Grade II” acute cholecystitis is associated with any one of the following conditions.
1. Elevated WBC count (>18000/mm³)
2. Palpable tender mass in the right upper abdominal quadrant
3. Duration of complaints>72h
4. Marked local inflammation (gangrenous cholecystitis, pericholecystic abscess, hepatic abscess, biliary peritonitis, emphysematous cholecystitis)
(a: Laparoscopic surgery should be performed within 96h of the onset of acute cholecystitis)

**Grade I (Mild) acute cholecystitis**

“Grade I” acute cholecystitis does not meet the criteria of “Grade III” or “Grade II” acute cholecystitis. It can also be defined as acute cholecystitis in a healthy patient with no organ dysfunction and mild inflammatory changes in the gallbladder, making cholecystectomy a safe and low-risk operative procedure.

Cited from Ref.[5]
The TG13 severity assessment criteria of acute cholecystitis was judged from numerous validation studies as useful indicators in clinical practice and adopted as TG18 severity assessment criteria without any modification.

**Fig. 1** Forest plot
Fig. 2 Typical ultrasound images of acute cholecystitis

Fig. 3 Typical ultrasound images of acute cholecystitis
**Fig. 4** Typical MR images of acute cholecystitis comparing contrast-enhanced CT

**Fig. 5** Typical MR images and MRCP of acute cholecystitis
Fig. 6 Typical CT images of gangrenous cholecystitis

Fig. 7 Typical CT, US, and MRI findings of gangrenous cholecystitis
Fig. 8 Public hearing final voting outcome

Question
Do you agree the suggestion that TG13 diagnostic criteria & severity grading would be adopted TG18 without any modification?

① Yes
89.3%

② No
10.7%